antibody_research

The 15th World Bispecifics Summit in Boston showcased breakthroughs. Biointron shares highlights shaping the future of bispecific antibody therapeutics.

Discover how phage display technology enables high-throughput screening of antibodies, peptides, and therapeutic proteins to accelerate drug discovery and protein engineering.

The 12th Immuno-Oncology Summit in Philadelphia spotlighted antibody therapeutics. Biointron shares event highlights driving progress in cancer immunotherapy.

BIX 2024 in Seoul spotlighted biotech and antibody advances. Biointron reports event highlights shaping innovation across discovery, development, and therapeutics.

Explore key highlights from PEGS 2024, featuring breakthroughs in antibody engineering, immunotherapy, ADC development, AI-driven discovery, and protein science.

The 4th Fc-Mediated Function Summit in Boston showcased Fc engineering advances. Biointron reports key insights driving next-generation antibody therapeutics.

AACR 2024 in San Diego spotlighted breakthroughs in cancer research. Biointron shares highlights on antibody therapeutics, discovery platforms, and translational science.

Explore key highlights from Biologics 2024, including advances in ADCs, AI-driven drug discovery, peptide therapeutics, and next-generation biologics innovation.

Biointron’s ISO 9001:2015-certified manufacturing standards ensure reliable, high-quality antibody production with rigorous QC processes and global CRO expertise.

Antibody labeling matters. Compare conjugation chemistries, optimize labeling degree, and master QC checks that ensure bright, specific, and reproducible results.

PepTalk 2024 delivered key insights into antibody development. Explore highlights on formulation, analytics, and modalities that shape the future of biotech innovation.

Beyond ELISA, discover multiplexed, label-free, and rapid immunoassays. Learn where they excel, how they are validated, and their role in modern diagnostics.

Explore how monoclonal antibodies combat COVID-19 by neutralizing SARS-CoV-2, including therapies like Actemra, challenges from emerging variants and Biointron’s antibody research.

How ELISA kits achieve specific, reliable readouts: key components, curve fitting, common pitfalls, and QC practices that keep results trustworthy across studies.

Compare delivery options for antibody‑based therapies—conjugates, nanoparticles, liposomes, and long‑acting platforms—to improve exposure, precision, and patient safety.